PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.77% for the 0-month period ending 2013-09-06, per its 10-Q filed 2015-05-15.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2015-05-15
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2012 was 0.71%, a 53.90% decline from fiscal 2011.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2011 was 1.54%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|
| 2013-09-06 | 1.77% 10-Q · filed 2015-05-15 | |
| 2013-09-05 | 1.85% 10-Q · filed 2015-05-15 | |
| 2012-06-30 | 0.71% 10-K · filed 2013-09-30 | |
| 2011-06-30 | 1.54% 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |